Skip to main content
. 2005 Sep 14;25(37):8451–8456. doi: 10.1523/JNEUROSCI.2349-05.2005

Figure 3.


Figure 3.

Western blots showing levels of PrP after treatment with MEK1/2 inhibitor U0126. A, ScGT1-1 cells treated with the MEK inhibitor U0126 (2 μm) in DMEM with 1% serum for 5 d. B, ScGT1-1 cells treated with U0126 (4 μm) in DMEM with 10% serum or in NB for 5 d. C, ScGT1-1 cells treated with U0126 (2 μm) in combinations with leupeptin or PPS for 4 d. D, Uninfected GT1-1 cells treated with U0126 (2 μm) in DMEM with 1% serum for 5 d.